A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.

The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.

The FDA has approved Journavx, a new non-opioid pain medication designed to reduce addiction and overdose risks.

A network of nerves similar to wires runs all through the human body, from the tips of your fingers and toes, through your ...

The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or ...

On Thursday, in a major step forward in pain management, the U.S. Food and Drug Administration has approved a new nonopioid ...

The FDA recently approved Vertex Pharmaceuticals Incorporated’s Journavx (suzetrigine), a first-in-class non-opioid medication for treating moderate to severe acute pain in adults. Journavx, approved ...

Cebranopadol reduced pain intensity in patients following abdominoplasty surgery in the ALLEVIATE-1 clinical trial.

Insights from a study on GLP-1 receptor agonists reveal benefits for cardiometabolic health, with notable risks for ...

A dysfunctional signaling pathway in the hippocampus has been linked to chronic pain-related memory impairment in mice.

The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...